|
ZNF217 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.05200350839641E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.47539774736561E-11 |
| Normal-vs-Stage2 |
3.032600E-01 |
| Normal-vs-Stage3 |
8.95049999671826E-08 |
| Normal-vs-Stage4 |
1.36919999782492E-08 |
| Stage1-vs-Stage2 |
1.998150E-03 |
| Stage1-vs-Stage3 |
6.910400E-01 |
| Stage1-vs-Stage4 |
1.952600E-01 |
| Stage2-vs-Stage3 |
3.897600E-03 |
| Stage2-vs-Stage4 |
1.177230E-04 |
| Stage3-vs-Stage4 |
1.012630E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.02207131646992E-12 |
| Normal-vs-AfricanAmerican |
2.258500E-03 |
| Normal-vs-Asian |
3.65709999999853E-05 |
| Caucasian-vs-AfricanAmerican |
6.075600E-01 |
| Caucasian-vs-Asian |
8.984600E-01 |
| AfricanAmerican-vs-Asian |
6.041200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.00939999692073E-08 |
| Normal-vs-Female |
6.74109656984001E-11 |
| Male-vs-Female |
6.288600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.7918002898939E-11 |
| Normal-vs-Age(41-60Yrs) |
1.84139999914734E-08 |
| Normal-vs-Age(61-80Yrs) |
1.376460E-04 |
| Normal-vs-Age(81-100Yrs) |
2.500900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.382000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.966300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.523800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.913200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.474800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.536400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.032200E-01 |
| Classical-VS-Follicular |
1.62447832963153E-12 |
| Classical-VS-Other |
1.812150E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.31006316905768E-12 |
| Tall-VS-Other |
5.853500E-02 |
| Tall-VS-Normal |
2.7317999973242E-08 |
| Follicular-VS-Other |
3.743800E-02 |
| Follicular-VS-Normal |
1.087980E-01 |
| Other-VS-Normal |
7.163700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.351380E-04 |
| Normal-vs-N1 |
2.27639999961227E-07 |
| N0-vs-N1 |
2.064400E-03 |
|
|
